MondayNightIBD | Lymphoma Risks in IBD #Back2Basics | 2/27/2023
Post-Survey & Application for CME Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. Where are you in your career?

IBD Specialist

General GI

Fellow/Trainee

APP

PharmD

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. Which population could benefit from testing for EBV serology before starting thiopurines?

Women < age 35

Men < age 35

Women > age 50

Men > age 50

Question Title

* 4. You are starting a 22 year-old male with severe Crohn’s ileitis on IFX and you recommend combination therapy with thiopurine to prevent anti-drug antibodies formation. He is concerned about the increased risk of lymphoma with combination therapy.
What information do you share with him about the risk of lymphoma with AZA/6MP to reach a shared decision?

He is not at increased risk because of his age

Risk increased only if he is EBV +

Risk increased after 1-2 years of AZA/6MP use

Risk persists after cessation of AZA/6MP

EVALUATION FORM

Question Title

* 5. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Strongly agree	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Agree	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Disagree	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Strongly disagree
TRANSLATE best practices for difficult-to-treat patients with IBD within clinical practice	TRANSLATE best practices for difficult-to-treat patients with IBD within clinical practice Strongly agree	TRANSLATE best practices for difficult-to-treat patients with IBD within clinical practice Agree	TRANSLATE best practices for difficult-to-treat patients with IBD within clinical practice Disagree	TRANSLATE best practices for difficult-to-treat patients with IBD within clinical practice Strongly disagree
EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Strongly agree	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Agree	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Disagree	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Strongly disagree
EMPLOY a patient-centered approach in IBD shared-decision making	EMPLOY a patient-centered approach in IBD shared-decision making Strongly agree	EMPLOY a patient-centered approach in IBD shared-decision making Agree	EMPLOY a patient-centered approach in IBD shared-decision making Disagree	EMPLOY a patient-centered approach in IBD shared-decision making Strongly disagree

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree
The educational resources provided to me at the educational activity are useful to my practice	The educational resources provided to me at the educational activity are useful to my practice Strongly agree	The educational resources provided to me at the educational activity are useful to my practice Agree	The educational resources provided to me at the educational activity are useful to my practice Disagree	The educational resources provided to me at the educational activity are useful to my practice Strongly disagree

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Improved diagnosis/patient assessment

Useful therapies and appropriate uses

Cutting-edge science in this therapeutic area

Best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Patient adherence/resistance to change

Other (please specify)

Question Title

* 12. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Lymphoma Risks in IBD #Back2Basics" and claim 1.0 AMA PRA Category 1 Credit^TM.

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

MondayNightIBD | Lymphoma Risks in IBD #Back2Basics | 2/27/2023 *Post-Survey & Application for CME Credit*

Question Title

* 1. Where are you in your career?

Question Title

* 2. What is your community of practice?

Question Title

* 3. Which population could benefit from testing for EBV serology before starting thiopurines?

Question Title

Question Title

* 5. Upon completion of this activity, I am able to:

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 12. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Lymphoma Risks in IBD #Back2Basics" and claim 1.0 AMA PRA Category 1 CreditTM.

MondayNightIBD | Lymphoma Risks in IBD #Back2Basics | 2/27/2023
Post-Survey & Application for CME Credit

* 12. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Lymphoma Risks in IBD #Back2Basics" and claim 1.0 AMA PRA Category 1 Credit^TM.